Replimune Group, Inc. $REPL Shares Sold by Trexquant Investment LP

Trexquant Investment LP lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 21.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 152,536 shares of the company’s stock after selling 42,056 shares during the quarter. Trexquant Investment LP’s holdings in Replimune Group were worth $1,487,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in REPL. Redmile Group LLC increased its holdings in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock valued at $59,406,000 after purchasing an additional 124,344 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock valued at $37,372,000 after purchasing an additional 237,185 shares during the last quarter. Tang Capital Management LLC increased its holdings in shares of Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. RTW Investments LP increased its holdings in shares of Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after purchasing an additional 931,223 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Replimune Group by 3.0% in the fourth quarter. Millennium Management LLC now owns 1,189,662 shares of the company’s stock valued at $14,407,000 after purchasing an additional 34,841 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

REPL stock opened at $6.33 on Friday. The business has a fifty day moving average of $7.02 and a two-hundred day moving average of $8.75. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The stock has a market cap of $494.12 million, a price-to-earnings ratio of -1.95 and a beta of 0.51. Replimune Group, Inc. has a 52-week low of $2.68 and a 52-week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analysts Set New Price Targets

REPL has been the subject of several recent research reports. Leerink Partnrs cut Replimune Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Tuesday, July 22nd. Leerink Partners reaffirmed a “market perform” rating and issued a $3.00 price target (down previously from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. HC Wainwright cut Replimune Group from a “buy” rating to a “neutral” rating in a report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $9.00 price target (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.50.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares of the company’s stock, valued at $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.20% of the stock is currently owned by company insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.